TeraImmune Revenue and Competitors
Estimated Revenue & Valuation
- TeraImmune's estimated annual revenue is currently $310k per year.
- TeraImmune's estimated revenue per employee is $155,000
Employee Data
- TeraImmune has 2 Employees.
- TeraImmune grew their employee count by -82% last year.
TeraImmune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director Regulatory Affairs | Reveal Email/Phone |
2 | Senior Scientist | Reveal Email/Phone |
3 | Cell Manufacturing lead | Reveal Email/Phone |
TeraImmune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $9.6M | 62 | -15% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $2.5M | 16 | 0% | N/A | N/A |
#8 | $7.4M | 48 | 0% | N/A | N/A |
#9 | $0.2M | 1 | -83% | N/A | N/A |
#10 | $1.7M | 11 | 22% | N/A | N/A |
What Is TeraImmune?
Key technical assets of TeraImmune 1) Expansion of human regulatory T cells in vitro 2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell) Grant awards 1) SBIR phase 1 (NHLBI, NIH) in April 2018 - grant for small businesses, scientifically verified 2) PACT program (NHLBI, NIH) in November 2018 - service grant supporting overall process development of the cell manufacturing: establishment of standard operating procedure (SOP), QA/QC and regulatory service
keywords:N/A
N/A
Total Funding
2
Number of Employees
$310k
Revenue (est)
-82%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Gaithersburg
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.3M | 2 | -60% | N/A |
#2 | $0.1M | 2 | 0% | N/A |
#3 | $0.3M | 2 | -60% | N/A |
#4 | $0.2M | 3 | 0% | N/A |
#5 | $0.3M | 4 | 0% | N/A |